Literature DB >> 34115951

Therapeutic Potential of Cannabidiol, Cannabidiolic Acid, and Cannabidiolic Acid Methyl Ester as Treatments for Nausea and Vomiting.

Erin M Rock1, Cheryl L Limebeer1, Roger G Pertwee2, Raphael Mechoulam3, Linda A Parker1.   

Abstract

Introduction: Nausea and vomiting are the most distressing symptoms reported by oncology patients undergoing anticancer treatment. With the currently available treatments, vomiting and especially nausea remain problematic, highlighting the need for alternative treatments. Discussion: Here we review in vitro and in vivo evidence for the effectiveness of the nonpsychoactive cannabinoid cannabidiol (CBD) in managing nausea and vomiting. In addition, we also review the evidence for CBD's acidic precursor, cannabidiolic acid (CBDA), and a methylated version of CBDA (CBDA-ME) in these phenomena. Finally, we explore the potential role of CBD in the treatment of cannabinoid hyperemesis syndrome. Conclusions: CBD has demonstrated efficacy in reducing nausea and vomiting, with CBDA and CBDA-ME being more potent. The data suggest a need for these compounds to be evaluated in clinical trials for their ability to reduce nausea and/or vomiting.

Entities:  

Keywords:  CBD; anti-emetic; behavior; cannabidiol; phytocannabinoids

Mesh:

Substances:

Year:  2021        PMID: 34115951      PMCID: PMC8380783          DOI: 10.1089/can.2021.0041

Source DB:  PubMed          Journal:  Cannabis Cannabinoid Res        ISSN: 2378-8763


  68 in total

1.  Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.

Authors:  A Thomas; G L Baillie; A M Phillips; R K Razdan; R A Ross; R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

Review 2.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

3.  Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.

Authors:  Sergio Poli-Bigelli; Jose Rodrigues-Pereira; Alexandra D Carides; Guoguang Julie Ma; Krista Eldridge; Anita Hipple; Judith K Evans; Kevin J Horgan; Francesca Lawson
Journal:  Cancer       Date:  2003-06-15       Impact factor: 6.860

4.  Exposure to a context previously associated with nausea elicits conditioned gaping in rats: a model of anticipatory nausea.

Authors:  Cheryl L Limebeer; Jon P Krohn; Shelley Cross-Mellor; Devin E Litt; Klaus-Peter Ossenkopp; Linda A Parker
Journal:  Behav Brain Res       Date:  2007-08-25       Impact factor: 3.332

5.  Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse.

Authors:  J H Allen; G M de Moore; R Heddle; J C Twartz
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

6.  Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew).

Authors:  Linda A Parker; Magdalena Kwiatkowska; Page Burton; Raphael Mechoulam
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

7.  A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping.

Authors:  Erin M Rock; Cheryl L Limebeer; Roshan Navaratnam; Martin A Sticht; Natasha Bonner; Kristin Engeland; Rachel Downey; Heather Morris; Meagan Jackson; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2014-03-05       Impact factor: 4.530

Review 8.  Cannabinoid Hyperemesis Syndrome: A Review of Potential Mechanisms.

Authors:  Marieka V DeVuono; Linda A Parker
Journal:  Cannabis Cannabinoid Res       Date:  2020-06-05

9.  The taste reactivity test. I. Mimetic responses to gustatory stimuli in neurologically normal rats.

Authors:  H J Grill; R Norgren
Journal:  Brain Res       Date:  1978-03-24       Impact factor: 3.252

10.  Single-Dose Pharmacokinetics and Preliminary Safety Assessment with Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and Cats.

Authors:  Kelly A Deabold; Wayne S Schwark; Lisa Wolf; Joseph J Wakshlag
Journal:  Animals (Basel)       Date:  2019-10-19       Impact factor: 2.752

View more
  2 in total

Review 1.  Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome.

Authors:  Stuart M Brierley; Beverley Greenwood-Van Meerveld; Giovanni Sarnelli; Keith A Sharkey; Martin Storr; Jan Tack
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-09-27       Impact factor: 73.082

Review 2.  Anti-Microbial Activity of Phytocannabinoids and Endocannabinoids in the Light of Their Physiological and Pathophysiological Roles.

Authors:  Ronit Vogt Sionov; Doron Steinberg
Journal:  Biomedicines       Date:  2022-03-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.